Exodus Point Capital Management, LP Bei Gene, Ltd. Transaction History
Exodus Point Capital Management, LP
- $14.7 Billion
- Q2 2024
A detailed history of Exodus Point Capital Management, LP transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 35,275 shares of BGNE stock, worth $7.92 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
35,275
Previous 18,171
94.13%
Holding current value
$7.92 Million
Previous $2.84 Million
77.09%
% of portfolio
0.03%
Previous 0.02%
Shares
7 transactions
Others Institutions Holding BGNE
# of Institutions
212Shares Held
45.1MCall Options Held
106KPut Options Held
93.1K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.37 Billion20.04% of portfolio
-
Capital International Investors Los Angeles, CA7.01MShares$1.57 Billion0.21% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1.16 Billion19.1% of portfolio
-
Primecap Management CO Pasadena, CA4.99MShares$1.12 Billion0.52% of portfolio
-
Baillie Gifford & CO3.68MShares$827 Million0.42% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.3B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...